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LipolysisWhite adipose tissue serves as a critical energy storage depot and endocrine organ. Adipocytes are subject to
numerous levels of regulation, including neuronal, endocrine and metabolic. While insulin is the classical en-
docrine regulator of lipid metabolism in adipose tissue, other important endocrine hormones also control
adipose tissue physiology. In this review, we will focus on the contribution of the pituitary in the modulation
of adipocyte function, through the direct release of growth hormone as well as via the regulation of the thy-
roid gland and release of thyroid hormone. This article is part of a Special Issue entitled: Modulation of Adi-
pose Tissue in Health and Disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
White adipose tissue (WAT) is the largest energy reserve in the
human body, and also plays a critical role as an endocrine organ in
healthy and diseased states. Not surprisingly, there exists a complex
network of communication between WAT and the brain, including
sympathetic innervation of fat pads as well as adipocyte-derived sig-
nals such as leptin that directly signals in the neuronal cells. In this re-
view, we will focus on the control of WAT physiology by signals
emanating from the pituitary gland, speciﬁcally in the regulation of
the hypothalamic/pituitary/thyroid axis as well as through the re-
lease of growth hormone into the systemic circulation.
The pituitary gland is considered the master endocrine gland due
to its regulation of numerous physiological processes. The posterior
pituitary is comprised of neuronal projections from the supraoptic
and paraventricular nuclei in the hypothalamus, which release oxyto-
cin and vasopressin into the general circulation. Oxytocin plays a crit-
ical role during child birth, while vasopressin acts on the kidney to
regulate water retention and thus blood volume/pressure and elec-
trolyte levels. In contrast, the anterior pituitary is a collection of endo-
crine cell types which are regulated by hypothalamic factors traveling
through the hypophyseal portal vessel. The ﬁve principal cell types of
the anterior pituitary are the corticotrophs, gonadotrophs, thyrotrophs,
lactotrophs and somatotrophs. Theﬁrst three cell types form the classical
hypothalamic–pituitary–adrenal, –gonadal and –thyroid axes, respec-
tively. Lactotrophs release prolactin while the somatotrophs produceion of Adipose Tissue in Health
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l rights reserved.growth hormone. Other reviews in this issue are covering the effects of
glucocorticoids and sex hormones on WAT function, so this review will
focus on the roles of the thyrotrophs and somatotrophs in the control
of thyroid hormone or growth hormone, and the effects of these two en-
docrine hormones on gene expression and metabolism in WAT.
2. Thyroid hormone
Thyroid hormone exerts dramatic effects on all major metabolic
tissues, including adipose tissue, liver, and muscle. The thyroid
gland is located in the neck on either side of the esophagus with the
two lobes connected by the isthmus. Thyroid hormone production
and release are controlled by a classical hypothalamic–pituitary axis
(Fig. 1). The hypothalamus releases thyrotropin-releasing hormone
(TRH), which stimulates the thyrotroph cells in the anterior pituitary
to synthesize and release thyroid stimulating hormone (TSH; also
called thyrotropin) into the general circulation. Binding of TSH to its
G-protein coupled receptor on thyroid follicular cells exerts pleiotro-
pic effects resulting in the enhanced synthesis and secretion of thy-
roid hormone. As with other hypothalamic/pituitary endocrine axes,
the end product thyroid hormone feeds back to decrease TRH and
TSH production.
Although the predominant form of thyroid hormone secreted by
the thyroid gland is levothyroxine (T4), the active form that binds
the thyroid hormone receptor (TR) is triiodothyronine (T3). The
conversion of T4 to T3 occurs via deiodinases, enzymes that are
expressed in liver, kidney, and other cells such as adipocytes [1].
Two of the deiodinase enzymes, Type 1 (or D1) and Type 2 (or D2)
deiodinases, remove an iodine from T4 to generate the active form
of thyroid hormone, T3. In contrast, Type 3 deiodinase (or D3)
removes a different iodine from T4 to generate an inactive form of
thyroid hormone, reverse T3 (rT3).
Fig. 1. Map of endocrine signaling mechanisms employed by the hypothalamic–pituitary
axis in the control of thyroid hormone (TH) and growth hormone (GH) secretion.
TH: Thyrotropin-releasing hormone (TRH) is secreted by cells in the arcuate nucleus of
the hypothalamus into the hypophyseal portal system where it stimulates thyrotrophs
in the anterior pituitary to release thyroid stimulating hormone (TSH) into the broader
circulation. Once in circulation, TSH binds to TSH receptors in the thyroid to activate pro-
duction of T4 and, to a lesser extent, T3 and their subsequent secretions into circulation. T4
is converted to T3 via deiodinases peripherally. Centrally, deiodinases in the hypothala-
mus and pituitary also convert T4 to T3, providing local feedback inhibition of the TRH
and TSH release. GH: Growth hormone releasing hormone (GHRH) is secreted by the ar-
cuate nucleus into the hypophyseal portal systemwhere it stimulates somatotrophs in the
anterior pituitary to release GH into the circulation. GHRH secretion can be increased by
ghrelin, originating from endocrine cells of the gut. Hypothalamic release of somatostatin
(SRIF) via the hypophyseal portal system inhibits GH secretion at the pituitary.
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termed thyroid hormone response elements and recruits other nucle-
ar factors to mediate activation or repression of gene transcription
depending on the underlying hormonal milieu and target DNA se-
quence [2]. In particular, on genes stimulated by thyroid hormone,
the TR recruits corepressors such as NCoR and SMRT in the absence
of T3. NCoR and SMRT in turn recruit a repression complex, including
in particular HDAC3, with histone deacetylase activity. Deacetylation
of lysine residues on histones renders chromatin in a transcriptionally
inactive state. The binding of T3 to the ligand-binding domain of the
TR results in a conformational change in the receptor, the release of
the corepressor complex, and the recruitment instead of numerous
coactivators. Coactivators have many functions; for example, some
coactivators acetylate lysine residues of histone, whereas others link
the TR complex with the basal transcriptional machinery. The net re-
sult of these various processes is to increase transcription of target
genes. There are actually multiple TR isoforms encoded by two sepa-
rate genes (TRα and TRβ). These TR isoforms exhibit tissue-speciﬁc
distribution patterns, and TRα1 may be particularly important for ad-
renergic signaling in adipose tissue [2], but TRβ1 may play an impor-
tant role in UCP 1 expression in BAT [3].
Thyroid hormone plays a crucial role in brain development in the
developing fetus, growth in children and regulates numerous pro-
cesses in the adult body, including basal metabolic rate, energy
expenditure, and thermogenesis. Thyroid hormone also regulates
organ physiology such as heart rate and contractile function. Clinical-
ly, patients with hypothyroidism (i.e., an underactive thyroid gland)
often note weight gain and increased fat mass, though the effect actu-
ally remains somewhat controversial [4]. It is clear, though, that thy-
roid hormone is one of the major endocrine mediators of the basal
metabolic rate [5]. In brown adipose tissue (BAT), thyroid hormone
is a regulator of UCP1 expression, and via this mechanism thyroid
hormone regulates adaptive thermogenesis [6]. Here we will focus
primarily on the effects of thyroid hormone on white adipose tissue
(WAT) differentiation and function.2.1. Thyroid hormone and adipogenesis
Adipocyte differentiation, or adipogenesis, proceeds by an orderly
series of events and depends on the expression of key transcription
factors such as C/EBP isoforms and PPARγ [7]. Initially, proliferation
of adipocyte precursors occurs, whereas differentiation into lipid-
laden adipocytes occurs after this round of proliferation takes place.
Thyroid hormone leads to distinct effects depending on the particular
stage of this process [8]. Initially, thyroid hormone suppresses prolif-
eration of the adipocyte precursors [9]. Interestingly, there is also ev-
idence that Type 3 deiodinase activity increases during this phase as
well [10], suggesting that local down-regulation of T3 levels may be
important to allow the proliferative stage of adipogenesis to proceed.
In contrast, thyroid hormone has different effects during the later
stages of adipogenesis. Carmona et al. showed that C/EBPα, a major
transcriptional regulator of adipogenesis, inﬂuences thyroid hormone
action in BAT in multiple ways. For example, deiodinase activity was
decreased in BAT of C/EBPα knock-out mice, which resulted in signif-
icantly lower T3 content [11]. To more directly study the effects of TRs
on adipogenesis, Mishra et al. generated 3 T3-L1 cell line variants ex-
pressing mutant thyroid hormone receptors that exhibit impaired
thyroid hormone signaling [12]. Interestingly 3 T3-L1 adipogenesis
was decreased in these cell lines. In addition, this group was able to
clarify TR isoform requirements by generating TR isoform-speciﬁc
mutations. Through this process, they showed that the TRα1 isoform
was particularly important for adipogenesis. Interestingly, PPARγ and
C/EBPα expression was decreased in the mutant cell lines, and TR was
recruited to the C/EBPα promoter [12]. Other studies suggest that the
mutant TRα1 could interfere with PPARγ transcriptional activity [13]
and in general there may be additional pathways of cross-talk be-
tween TRs and PPARs [14]. To assess the role of TRs on adipogenesis
in vivo, Ying et al. created a mouse expressing a mutant TRα1 [13].
As might be expected from the in vitro data above, these mice had a
lean phenotype due to decreased WAT mass [13]. In contrast, mice
expressing a mutant TRβ receptor had normal WAT mass, though
there was excess lipid in the liver of these mice [3]. Thus, thyroid hor-
mone is an important regulator of adipogenesis, and its actions are
speciﬁcally dependent on the TRα1 isoform, though TRβ1 plays im-
portant roles in other metabolic tissues.2.2. Thyroid hormone modulation of lipogenesis and lipolysis
The adipocyte stores energy in times of caloric excess through the
process of lipogenesis, whereas adipocyte triglyceride is broken down
to glycerol and free fatty acids (lipolysis) during periods of fasting.
Counter-intuitively, thyroid hormone enhances both of these pro-
cesses. Although the exact mechanism by which thyroid hormone
stimulates lipolysis is not fully understood, it has been known
for many years that thyroid hormone enhances catecholamine-
mediated lipolysis in both isolated adipocytes [15] and patients with
clinical hyperthyroidism [16]. Hyperthyroidism increases β-2 adren-
ergic receptor number and appears to increase signaling at the
post-receptor level as well [16]. The speciﬁc mechanisms by which
thyroid hormone regulates adrenergic receptor function at a post-
receptor level, though, have been controversial. Most likely, thyroid
hormone acts at many levels of the adrenergic signaling pathway
[17], including cAMP formation, alteration in G-protein subunit
expression, and through decreasing phosphodiesterase activity [18].
Thyroid hormone also regulates the sympathetic nervous system
centrally, but in this case excess thyroid hormone decreases central
sympathetic outﬂow [17]. Thus, most of the clinical effects of
hyperthyroidism mediated by the sympathetic nervous system do
not depend on central regulation of sympathetic outﬂow, but
instead appear to result from altered responses to catecholamine
peripherally.
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transcription of key lipogenic genes [19,20]. The mouse model of de-
creased TRα1 signaling noted above was also studied for lipogenic
function, and the expression of many lipogenic genes was found to
be speciﬁcally decreased [13]. In an older study of the effects of thy-
roid hormone on rat lipogenesis, lipogenesis increased within 1 day
and reached a plateau after 4–5 days of thyroid hormone treatment
[21]; overall, due to the complex and partially antagonistic effects of
increased lipogenesis and lipolysis, total body fat stores fell about
50% by day 6 of treatment due to increased energy expenditure.2.3. Thyroid hormone modulation of adipokine secretion
While it used to be thought that the sole function of the adipocyte
was to store energy as triglyceride, it is now known that adipocytes
are also active endocrine cells that secrete hormones. These hor-
mones are called adipokines (or adipocytokines) and include factors
that regulate feeding behavior and insulin sensitivity [22]. Interest-
ingly, adipokine secretion is dysregulated in obesity, leading to
overproduction of insulin resistance factors, but decreased produc-
tion of adiponectin, which increases insulin sensitivity. The ﬁrst
adipokine to be ﬁrmly established was leptin. Leptin was originally
identiﬁed by analysis of the ob/ob mouse, which is hyperphagic and
obese. It was determined that the ob/ob mouse lacked a factor secret-
ed by adipocytes that was subsequently termed leptin. Leptin has
more recently been implicated not only in feeding behavior, but
also in neuroendocrine function [23]. Interestingly most forms of
human obesity are not associated with leptin deﬁciency, but instead
are characterized by leptin resistance. The effects of thyroid dysfunc-
tion on leptin levels have been studied by multiple groups. Though
some studies have shown leptin abnormalities, most studies suggest
that leptin levels are normal in thyroid dysfunction [24]. In a rat
study, leptin levels did correlate with thyroid status, but this was
only indirectly through changes in fat pad size [25]. Thus, the alter-
ation in leptin secretion associated with changes in thyroid status
appears to be minimal. In contrast, leptin itself stimulates the hypo-
thalamic–pituitary–thyroid axis by enhancing TRH gene expres-
sion [26]. The inﬂuence of thyroid dysfunction on other adipokines
is also not well deﬁned, with some studies suggesting changes not
conﬁrmed by other groups. There are a few studies, however, to sug-
gest that thyroid hormone status may correlate with adiponectin
levels [27].2.4. Type 2 deiodinase and the local control of thyroid hormone
production
Type 2 deiodinase is the enzyme most involved in the local pro-
duction of T3 from T4 in target tissues. Tissues that express high
levels of Type 2 deiodinase therefore exhibit relatively high local
levels of T3 compared to other cell types [28]. Adipose tissue is one
of the major organs to express Type 2 deiodinase. Although both
WAT and BAT express Type 2 deiodinase, the pivotal role of this en-
zyme has been studied particularly well in BAT. Here, the enzyme
promotes T3 production to increase UCP1 expression and regulate
adaptive thermogenesis [5]. Sympathetic nervous system activity
stimulates Type 2 deiodinase as well, in yet another interaction
between the thyroid hormone axis and sympathetic nervous sys-
tem in adipose tissue biology. Surprisingly, Type 2 deiodinase
knock-out mice do not develop obesity when reared at room tem-
perature [29], but this is due to the chronic increase in BAT sympa-
thetic activity at this temperature. In contrast, when these mice are
reared at thermoneutrality, they develop obesity and glucose intol-
erance, clearly pointing to a role for local T3 generation in BAT
function [29].2.5. Summary of thyroid hormone action on adipocytes
Thyroid hormone stimulates diverse and even seemingly contra-
dictory aspects of adipose tissue physiology, including adipogenesis,
lipogenesis, and lipolysis. These actions are dependent on speciﬁc
isoforms of the thyroid hormone receptor, and rely on local activation
of thyroid hormone via deiodinase enzymes. Thyroid hormone signal-
ing interacts closely with the adrenergic signaling pathway, and there
is extensive cross-talk between the TR and other adipocyte transcription
factors such as PPAR and C/EBP.With the advent of tissue-speciﬁc and/or
isoform-speciﬁc thyroid hormone analogs, it may be possible in the fu-
ture tomodify thyroid hormone signaling pathways to treat variousmet-
abolic disorders including obesity and the dyslipidemias [30].
3. Growth hormone
Growth hormone is a powerful modulator of bone, liver, muscle,
and adipose tissue growth and metabolism. GH is secreted from
somatotrophs in the anterior pituitary in response to regulatory sig-
nals from the hypothalamus. While there are two genes encoding
human GH, GH1 and GH2, only GH1 is expressed in somatotrophs.
GH2 is only expressed during pregnancy in the placenta and has
very similar biological activity to protein expressed from the GH1
gene. For these reasons, placental GH is beyond the scope of this re-
view, and will not be discussed (but was extensively reviewed in
[31–33]). GH1 mRNA is alternatively spliced, yielding either a major,
full length product (22.1 kDa), or a minor shorter product (20.3 kDa)
in a 20:1 ratio, respectively. Both isoforms have equivalent biological
activities in humans as measured during a 16-week infusion study
conducted with growth hormone-deﬁcient adults [34]. GH is capable
of dimerization and oligomerization, but these associations do not
seem to qualitatively affect its biological activity [35].
GH secretion from the pituitary is regulated by growth hormone
releasing factor (GHRH), somatostatin (SRIF), and ghrelin [36] (Fig. 1).
GHRH is released from the hypothalamus and activates pulsatile GH se-
cretion [37] through a GHRH receptor-mediated signal cascade raising
intracellular Ca2+ levels, resulting in SNAP/SNARE-mediated fusion
of secretory vesicles with the cell membrane for GH exocytosis [36].
The major counter-regulatory hypothalamic hormone responsible for
inhibiting the release of GH is SRIF. Studies on chickens suggest that
SRIF exerts its inhibitory effects by suppressing Ca2+ inﬂux and elevat-
ing K+ inﬂux, a process mediated by SRIF receptors on the cell surface
of somatotrophs [36]. Ghrelin arising from the intestinal tract is an acti-
vator of GH secretion, albeit acting indirectly by inducing hypothalamic
release of GHRH [36,38].
Growth hormone in normal adult humans is released in short,
small pulses during waking hours after meals [39] and rises sharply
with the onset of sleep, reaching a peak approximately 1–2 h later
[40,41]. Circulating GH eventually decreases throughout the remainder
of the night until waking, occasionally undergoing progressively-
smaller increases throughout the night [42]. This initial rise inGHoccurs
within a few minutes of the onset of sleep, even if sleep is delayed
[40,43] or brought about at an unnatural time [44,45]. Recent studies
have demonstrated that pulsatile secretion of GH can be uncoupled
from the onset of slow-wave sleep and can occur independently when
slow-wave sleep is delayed [46], or when the sleep schedule is severely
disrupted by odd-hours shift work [47] or semichronic partial sleep loss
[48]. These ﬁndings highlight the need for more investigation into the
exact physiological triggers of GH secretion.
Once in circulation, GH bioavailability is determined by a variety
of factors, including the rate of pituitary GH release, the amount of
GH sequestered by GH binding protein (GHBP), and glomerular clear-
ance of circulating GH. Approximately 45% of circulating GH is bound
to GHBP, preventing its interaction with the GH receptor. In humans,
GHBP is produced through proteolytic cleavage of the GH receptor,
which releases the extracellular ligand-binding portion of the receptor
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mately cleaved to form GHBP, representing at least 75% of GHBP pro-
duced [49]. It is yet unclear whether human adipocytes produce GHBP
from cleavage of the GH receptor. The GH/GHBP complex is large
enough to prevent glomerular ﬁltration of bound GH, increasing the
plasma half-life of GH bymore than 3-fold [49]. These combined effects
increase the stability and bioavailability of GH in circulation, despite its
characteristically-pulsatile secretion.
3.1. Growth hormone receptor
At the cellular level, human growth hormone (hGH) signal transduc-
tion occurs via the hGH receptor (hGHR), a cytokine receptor-family
G-protein-coupled receptor consisting of 3 distinct domains: extracellu-
lar, transmembrane, and cytoplasmic. The extracellular domain of hGHR
shares signiﬁcant structural homology with the prolactin- and IL-6 re-
ceptors [50,51], a feature manifested by growth hormone's weak ability
to stimulate the prolactin receptor [51,52]. There are 13 different tran-
scripts that encode the full-length hGHR, each differing only in its
5′ UTR, ultimately producing identical GH receptor protein. Each alter-
native transcript is generated through variations in splicing of the
same GHR gene. Of these, 6 have been identiﬁed in human adipocytes
[53,54]. The proportion of these transcripts changes markedly from
preadipocytes to differentiated adipocytes, ultimately resulting in the
predominant transcription (>80%) of a single isoform, a farmore homo-
geneous combination than in the liver [53,55,56]. Ultimately, this variety
of alternative 5′ regions is thought to be an indicator of the variety of
transcriptional activation mechanisms (different transcription factor-
mediated activation of transcription) [53,57,58], and it remains to be
seen whether the different 5′ untranslated regions serve different regu-
latory functions.
3.2. Growth hormone modulation of lipogenesis and lipolysis
Adipose tissue consists predominantly of a single lipid droplet
formed by stored triglycerides that can be hydrolyzed to form
free fatty acids and glycerol during times of energy demand. Both
lipolysis and lipogenesis are tightly-regulated processes existing
in a dynamic equilibrium, responding to the integrated signals of
several different hormones including insulin, catecholamines, glu-
cocorticoids, thyroid hormone, and natriuretic peptides. Though
GH has long been recognized as playing a role in the regulation of
lipolysis, its acute effects in humans appear to be weaker, and
chronic effects stronger, than murine studies [59], indicating a
strongly species-speciﬁc GH effect in humans. For this reason, the
following paragraphs on the mechanisms of GH intracellular sig-
naling in WAT have been primarily limited to ﬁndings obtained
from human-based studies.
3.2.1. STAT5
GH receptor activation leads to the phosphorylation of tyrosine
residues on STAT5, activating STAT5 [60]. Once activated, STAT5
homodimerizes and translocates to the nucleus where it regulates
transcription of several cell cycle and metabolic genes such as
PPAR-gamma, FAS, and PDK4 [60–62]. Human studies on STAT5 acti-
vation by GH have yielded mixed results, but more consistently show
a STAT5-mediated effect of GH on lipolysis. Studies have found that
STAT5 phosphorylation trended higher or was signiﬁcantly increased
by either a bolus or intravenous infusion of STAT5, and that the net ef-
fect of GH administration is increased lipolysis [63–65]. These obser-
vations are supported by multiple mouse-based studies in which the
presence of STAT5 was shown to be necessary for GH-mediated acti-
vation of lipolysis [66,67]. These results suggest that STAT5 mediates
at least some of the lipolytic effects of GH signaling in humans
through transcriptional regulation.3.2.2. Lipoprotein lipase (LPL)
Studies in humans and human-derived tissues on the effects of GH
on LPL are mixed, with some indicating that GH has no signiﬁcant ef-
fect [68–70], or an inhibitory effect on LPL transcription or activity
[71,72]. The apparent lack of LPL effects during acute treatments,
taken in the context of inhibitory LPL effects during chronic GH treat-
ment, suggests that changes in LPL expression or activity due to GH
treatment may be secondary, resulting from other initial GH-mediated
changes in lipid metabolism (such as changes in net lipolysis rates
through HSL activity — see below).
3.2.3. Hormone sensitive lipase (HSL)
Rat studies suggested that GH was capable of modulating HSL ac-
tivity or expression [73], but more recent human-based studies have
found that GH activates lipolysis without changing adipocyte HSL
mRNA levels [74], suggesting activation of HSL by phosphoryla-
tion and/or regulation of other lipases. Suppression of nocturnal
circulating GH in humans decreased subcutaneous-adipose HSL activ-
ity [68]. Another study conducted to examine the effects of GH treat-
ment on a very low-calorie diet in obese, premenopausal women
showed no GH-related change in HSL activity, but the authors could
not rule out that the effects of GH on HSL were not overshadowed
by the aggressive dietary intervention [69]. This study raises the
possibility that the GH-activation pathway for HSL may overlap with
caloric balance/starvation sensing pathways. These studies taken to-
gether reveal that HSL activity is likely up-regulated in response to
GH signal transduction in adipocytes in a transcription-independent
manner.
3.2.4. CIDE-A
One powerful regulator of lipolysis is the cell death-inducing
DFFA-like effector A (CIDE-A), a lipid droplet-associating protein
highly expressed in human adipose tissue that promotes triglyceride
storage [75]. Unfortunately, the current literature regarding CIDE-A
regulation and physiological signiﬁcance in the context of GH signal-
ing is not conclusive. Mice without functional GHR or GHBP have
lower CIDE-A mRNA expression and larger adipocytes in subcutane-
ous adipose depots, which indicates that GH promotes expression of
CIDE-A [76]. Physiological observation revealed that obese humans
have two-fold lower subcutaneous adipose tissue CIDE-A mRNA ex-
pression [77], and lower circulating GH [78]. These correlations indi-
cate that GH promotes mRNA expression of CIDE-A. This would be
counter-intuitive, as elevated expression of CIDE-A would be anti-
lipolytic, and therefore in opposition to the well-characterized lipo-
lytic effects of GH in adipose tissue. Further complicating matters is
that hypopituitary males receiving GH supplementation showed a
2.8-fold decrease in subcutaneous adipose tissue CIDE-A mRNA
expression [74], which would indicate that GH has a suppressive ef-
fect on CIDE-A. This ﬁnding would be consistent with the known
lipid-droplet-shrinking properties of GH activity in the adipocyte. Dif-
ferences between these models must be resolved or new paradigms
used for investigation before further conclusions can be drawn.
3.3. Growth hormone modulation of adipokines
Leptin is an important adipocyte-derived endocrine hormone that
regulates several important processes including feeding behavior, and
basal metabolic rate through regulation of the hypothalamic–pituitary–
thyroid axis. Circulating leptin levels are proportional to energy stores
in adipose tissue, and thus parallel changes in adiposity. The observation
has repeatedly been made, in both animal models and human models,
that elevated GH is associated with increased leanmass and reduced ad-
iposity [80–83], while GH resistance [84,85] and GH deﬁciency [86] are
associated with increased fat mass and circulating leptin. In addition to
reduced fatmass, patientswith acromegaly also exhibit lower circulating
leptin, in one study even lower than in sex-matched, age-matched,
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question of whether GH activity exerts a direct effect on leptin expres-
sion and/or secretion. Human studies in vivo have repeatedly failed to
show a causal link between growth hormone activity and changes in cir-
culating leptin that aren't ﬁrst preceded by a change in fatmass, whether
examining GH deﬁciency, GH resistance, or acromegaly.
During either acute or chronic GH administration in elderly
GH-deﬁcient patients, circulating leptin remained unchanged, except
where there was also a change in fat mass [87]. Additionally,
GH-resistant adults provided GH for 7 days and acromegaly patients
cured by adenomectomy showed no apparent correlation between
GH levels and circulating leptin [84,88]. Pharmacological intervention
with a somatostatin analog to reduce GH secretion in patients with
acromegaly reduced GH and IGF-1 levels after 8 weeks of treatment,
but only increased leptin levels after 6 months of treatment, during
which time patients had gained fat mass [89]. In the same study, sur-
gical intervention lowered GH levels even further than drug interven-
tion, and also increased leptin levels. The lack of immediate temporal
correlation between GH levels and leptin levels suggests that GH does
not directly control leptin levels in humans. Acromegaly patients
before- and 2-months after trans-sphenoidal surgery showed elevat-
ed leptin levels, but the circadian rhythmicity was unchanged from
pre- to post-surgery [90] despite a greater than 9-fold decrease in circu-
lating GH. Whereas the nocturnal rise in GH is directly related to the
onset of sleep (see above), it has been shown that the normal circadian
increase in leptin is directly related to meal timing [91], strongly indi-
cating that leptin secretion is regulated in aGH-independent fashion. Fi-
nally, healthy young men given a combination of glucocorticoids and
growth hormone showed no independent effect of GH on serum leptin
[92]. These studies concertedly show that there is no demonstrable,
physiologically-signiﬁcant connection between leptin levels and GH
in vivo.
3.4. Potentiation of metabolic response to catecholamines
In addition to causing increased adipocyte lipolysis per-se, GH also
potentiates the lipolytic response to catecholamines. Growth hormone-
deﬁcient adults given GH hormone treatment for 6 months show
signiﬁcantly elevated lipolysis in response to epinephrine in isolated
subcutaneous abdominal adipocytes. This is thought to occur through
enhancement of beta-adrenergic receptor-stimulated signal transduc-
tion [79].
3.5. GH therapy as treatment for metabolic syndrome/obesity
With the increased prevalence of obesity and associated metabolic
diseases in humans across the world, the need for approaches to pro-
mote weight loss has become ever more pressing. Obesity is associat-
ed with lower basal [93–95] and stimulated [96–98] GH secretion.
Given the reduced adiposity and increased lean muscle mass ob-
served in patients with acromegaly [99], investigators have asked
whether GH may be effective as a therapeutic for excessive adiposity,
either by itself or in concert with other interventions. A recent
meta-analysis of GH interventions concluded that GH administration
does not have a clear impact on adiposity or BMI, but they indicated
that more nuanced beneﬁts may be present, particularly with respect
to variables such as age or duration of treatment [100]. A more de-
tailed examination of the data is called for, with special attention to
more recent GH-related studies, to examine the potential utility of
GH in reducing adiposity in morbidly obese individuals.
3.5.1. GH monotherapy
The ﬁndings of GH-only therapy are mixed in adult patients, with
a few studies showing no signiﬁcant changes in adiposity or metabol-
ic proﬁle following daily administration of low doses of GH [101].
One study showed a decrease in glucose tolerance during acuteadministration of exogenous GH infusion [102], while another
showed that a bolus of GH did not [64]. The predominating ﬁndings,
however, are that long-term (≥6 months) daily administration of
GH has beneﬁcial consequences in obese or overweight individuals,
including an increase in lean muscle mass [72,103], decreased fat
mass [70,72,103–105], and/or improved insulin sensitivity [70]. Injec-
tion of GH-stimulating pharmacological agents such as Tesamorelin
has demonstrated similar effects to exogenous GH, with clear beneﬁts
to increased lean muscle mass, decreased adiposity, and unchanged
insulin sensitivity [106,107].
3.5.2. GH treatment with dietary intervention
As with GH-only intervention, the literature presents mixed
stories, with some reports of unchanged fat loss despite daily GH ad-
ministration [69,108]. GH administration in concert with dietary in-
tervention is beneﬁcial in a variety of ways. During weight loss from
caloric restriction, GH administration enhances the reduction of fat
mass [109,110] and/or prevents a decrease in lean mass [109,111].
In type II diabetes, caloric restriction combined with daily GH admin-
istration has also been shown to improve insulin sensitivity and plas-
ma lipid proﬁle [110,112]. The GH dosage and carbohydrate content
of the diet additionally appear to modify circulating lipids during ca-
loric restriction [113,114].
4. Overall conclusions
TH and GH are two important endocrine hormones that mediate
regulation of adipose tissue by the brain through the conduit of the
pituitary. Together with other neuronal and endocrine systems, they
contribute to the systemic coordination of energy intake, storage
and utilization by the body. As with any physiological process,
dysregulation of normal or GH action contributes to the pathophysi-
ology of human disease including obesity. More research is required
to fully understand the integrative role of TH and GH play in the in
the complex and interdependent regulation of adipose tissue.
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